Virtual Screening of Potent Inhibitors for *Mycobacterium tuberculosis* Arabinogalactan Synthesis

ABSTRACT

Background: Tuberculosis remains the most prevalent infectious disease, requiring the identification of new targets and drugs due to emerging drug resistance for *My-cobacterium tuberculosis*. Virtual screening has the potential to be highly valuable for identifying new drug candidates by searching through compound databases. The present study involved screening a library of around 3.5 million selected compounds from the ZINC20 database and a reference inhibitor library from literature to identify strong inhibitors against the Decaprenylphosphoryl-β-D-ribose 2'-epimerase (DprE1) enzyme of *M. tuberculosis* through virtual methods.

Methods: A two-step selection of compounds was carried out from the ZINC20 database using stringent reference physicochemical ranks based on the reference inhibitor library. The resulting library comprised 2700 compounds from the ZINC database along with 21 reference inhibitors from the literature exhibiting MICs of 10 μ M or lower. Docking simulations were performed for a total of 2721 compounds based on the AutoDock Vina tool using python-based computational drug discovery software, PyRx against the crystal structure of *M. tuberculosis* DprE1 enzyme (Protein Data Bank, PDB: 4P8K).

Results: After docking analysis of the selected final library (2721 in total), we determined 21 molecules as top-ranked compounds. The top-ranked compounds from the ZINC20 library had a Δ G in the range of -11 and -11.9 compared to -7.7 and -10.9 of the selected 21 reference inhibitors with MICs of 10 μ M or lower. Among the whole library, ZINC00009429240 and Ref3 emerged as the highest ranked compounds, exhibiting a Δ G value of -11.9 and -10.9, respectively. ZINC00009429240 and Ref3 were determined to show H-bond interactions with 228S and 418K versus 132H, 228S and 60Y, respectively.

Conclusion: Here, we virtually identified a largely distinct set of compounds as effective inhibitors for the DprE1 enzyme of *M. tuberculosis.* The data gathered in this study may have the potential to be developed into effective drug molecules.

Key Words: Bioinformatics, chemistry, medical microbiology.

INTRODUCTION

Tuberculosis (TB) is among the top 10 leading causes of death on a global scale, with more than 1.5 million deaths and a 10 million annual new diagnosis according to the World Health Organization.¹ Due to the highly contagious nature of TB and its airborne transmission, drug resistant strains become difficult to control. The global efforts for preventing TB includes early detection, vaccination, efficient treatment and surveillance.² Currently, TB treatment consists of four old drugs including pyrazinamide (PYR), isonia-zid (INH), ethambutol (EMB) and rifampicin (RFP) which are applied in combination. The incorrect use of the antibiotics resulted in the development of drug-resistant strains of *M. tuberculosis.*³ The current worldwide strategy to combat drug resistant *M. tuberculosis* strains has been directed towards the development of novel TB drugs, especially those with novel targets.⁴ TB drugs target and inhibit numerous essential pathways involved in cell wall formation (e.g., InhA, KasA, and Emb proteins), ATP synthase, nucleic acid synthesis (via DNA gyrase and topoisomerase IV inhibition), protein synthesis (targeting ribosomal proteins), fatty acid biosynthesis and many others.⁵

Over the past decade, new drugs have been approved for tuberculosis treatment. Some of these drugs target well-known important enzymes like InhA (enoyl-ACP reductase) while others effectively target different mechanisms to inhibit *M. tuberculosis*. Among

CC 0 S

Copyright@Author(s) - Available online at http://trendsinpharmacy.org/ Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Nurbanu Yaşar¹ D Ahmet Serhat Ayvaz² D Gülay Dilek³

¹Department of Medical Microbiology, University of Mersin, Faculty of Medicine, Mersin, Türkiye ²Department of Pharmaceutical Microbiology, Zonguldak Bülent Ecevit University, Faculty of Pharmacy, Zonguldak, Türkiye ³Department of Pharmaceutical Basic Sciences, Zonguldak Bülent Ecevit University, Faculty of Pharmacy, Zonguldak, Türkiye

Corresponding author: Gülay Dilek

Address: Department of Pharmaceutical Basic Sciences, Zonguldak Bülent Ecevit University, Faculty of Pharmacy, Zonguldak, Türkiye Email address: gulay.dilek@beun.edu.tr

Received: May 29, 2024 Revision Requested: June 6, 2024 Last Revision Received: June 9, 2024

Accepted: June 10, 2024 Publication Date: June 14, 2024

Cite this article as: Yaşar N, Ayvaz AS, Dilek G. Virtual screening of potent inhibitors for *Mycobacterium tuberculosis* arabinogalactan synthesis. *Trends Pharm*. 2024, 1, 9, doi: 10.5152/TrendsPharm.2024.23009 these targets, Decaprenylphosphoryl-β-D-ribose 2'-epimerase (DprE1) plays an important role in the biosynthesis of cell wall arabinogalactan. DprE1 is the target of two recently approved antituberculosis drugs, including delamanid (DLM) and pretomanid (PMD). These drugs are being used in the management of extensively drug-resistant TB (XDR TB).⁶

Drug screening aimed at inhibiting the mycolic acid synthesis through the targeting DprE1 has demonstrated significant promise in the development of novel drugs for tuberculosis.⁷⁻⁹ In recent years, computational methods have made it possible for screening of millions of potential drug candidates for the treatment of tuberculosis.¹⁰ In this study, we aimed to evaluate a large-scale of compounds via *in-silico* screening against DprE1 for the discovery of potential drug candidates for TB treatment.

MATERIAL AND METHODS

Construction of Compound Library And Preparation

The compounds used for the virtual screening were collected from the ZINC20 database (https://zinc20.docking.org).¹¹ The physicochemical properties of the DprE1 potent inhibitor library (included ~1519 compounds) from literature¹² were utilized for selecting compounds from ZINC20. The average values comprising standard deviations (SD) of molecular weight (MW), cLogP, H-bond donors, H-bond acceptors, topological polar surface area (TPSA), flexibility, rotatable bonds, druglikeness, and also toxicity properties were calculated from the potent DprE1 inhibitor library. In addition to physicochemical features, the compounds known to have MIC values lower than 10 μ M were also screened for determining a cut-off Gibbs free energy (Δ G, kcal/mol) value.

Selected compounds were chosen from the ZINC20 database based on their purchasability, 3D structures, reactivities, and reference values in the range of 2.5-4.57 for cLogP and 300-500 for MW as the first step of selection. In the second step, these collected compounds underwent evaluation using physicochemical descriptors other than cLogP and MW through Datawarrior v06.01 software.¹³ The reference range values used for selection were 70-120 for TPSA, 0.10-0.25 for flexibility, less than 10 for H-bond acceptors, less than 5 for H-bond donors, greater than 0 for druglikeness, and a range of 2-8 for rotatable bonds; in addition to avoiding high mutagenicity. Thus, the selection ensured compatibility to Lipinski's R05 rule¹⁴ even with some more strict parameters for a more accurate prediction for targeting *M.tuberculosis*.

Virtual Screening

Multiple docking simulations for the compounds selected were performed using the AutoDock Vina tool¹⁵ in python-based computational drug discovery software, PyRx¹⁶ against the crystal structure of *M. tuberculosis* DprE1 enzyme (Protein Data Bank, PDB: 4P8K).¹⁷ The crystal structure used contained a complex with a potent inhibitor, and the active cavity was determined to include the space where the inhibitor interacted. The dimensions of this cavity were as follows: center (x, y, z) = (16, -20, 1.5), and dimensions (x, y, z) = (11, 16, 14). The crystal structure of M. tuberculosis DprE1 enzyme was imported into the software and underwent protein preparation steps including removing unwanted molecules such as water, adding polar hydrogen and charge; then converting the prepared protein to .pdbqt format using PyRx automatically.

When preparing the ligands, all selected compounds from ZINC20 and the reference compounds from the literature¹² with minimum inhibitory concentrations lower than 10 μM were imported into PyRx. The integrated OpenBabel module was then used for multiple ligand minimization and conversion to .pdpgt format. Docking simulations for each ligand were run in 8 repetitions to calculate ΔG . After the docking simulations, only docked poses with lower total binding energy compared to those of reference compounds, with a root mean square deviation (RMSD) value \leq 2 Å, and with successful binding in the selected cavity space were accepted as top-ranked compounds. The inhibition constant (Ki) was calculated from the binding energy (ΔG) using the formula: Ki = exp(ΔG / RT) (R is the universal gas constant [1.985 × 10–3 kcal mol–1 K–1] and T is the temperature [298.15 K]). The compounds were visually evaluated using PyMOL Molecular Graphics System.¹⁸ 2D interaction profiles were obtained using Maestro v.11.8.012 of the Schrodinger 2018.4 (Schrodinger, LLC, New York, NY, 2018) Linux Ubuntu (2020) version.

Mutation Screening for the Interacting Amino Acids

DprE1 of *M. tuberculosis* has the potential for amino acid mutations. A mutation screening was conducted specifically for amino acid positions that interacted with reference inhibitors and top ranked compounds. Gene sequences related to DprE1 enzyme were gathered from Genbank (www.ncbi.nlm.nih.gov/genbank/), aligned, converted to amino acid sequences, and compared to the reference DprE1 sequence (NP_218307.1) of *M. tuberculosis* via BioEdit v7.7.1. It was assessed if there were any records of mutations at the positions where the compounds interacted.

RESULTS

In preparing the compound library in the ZINC20 database, we applied five basic selections based on molecular weight, cLogP, 3D structure, in-stock availability, and reactivity properties. The initial selection resulted in the collection and download of approximately 3.5 million compounds (accessed on March 15, 2024) in .sdf format. Subsequently importing the library into Datawarrior software led to a second selection process based on reference value ranges for H-bond donors, H-bond acceptors, topological polar surface area, flexibility, rotatable bonds, druglikeness criteria as well as toxicity properties. This rigorous process yielded a total of 2700 compounds with similar physicochemical descriptors clustering as those found in the potent DprE1 inhibitors' library.¹² Virtual screening involved 2700 compounds from the ZINC20 database and 21 reference inhibitors with a MIC of 10 μ M or lower selected from the inhibitor library. The inhibitors with the highest MICs reported a ΔG in the range of -7.7 and -10.9. Ref3 showed the strongest interaction among the selected 21 inhibitors in the reference inhibitor library, with a ΔG of -10.9. A total of 21 compounds from the ZINC20 library were identified as top-ranked ones, exhibiting lower binding energies than those of Ref3. The top-ranked compounds from the ZINC20 library had a ΔG in the range of -11 and -11.9. Within these, ZINC000009429240 was found to be the top-ranked compound with a ΔG of -11.9. From the 2D interaction maps of the top-ranked compounds of the reference and the ZINC20 library, H-bond interactions with 228S and 418K versus 132H, 228S and 60Y; hydrophobic interactions with 116P, 131I, 316P, 365V and 415Y versus 116P, 316P and 365V were determined for ZINC000009429240 and Ref3, respectively (Figure 1). Amino acids positions of 228S, 116P, 316P and 365V were found to be common

positions that interact with both ZINC000009429240 and Ref3. The names, structures as SMILE format, binding energies, and Ki values of reference compounds (with MICs lower than 10 μ M) as well

as the top-ranked 21 compounds of the library from the ZINC20 database are given in Table 1.

Table 1. Energies and Inhibition Constant (Ki) Values of T	p-Ranked Compounds from Reference ¹² and ZINC20 Libraries
--	--

Compound name	SMILES	Binding energy (∆G, kcal/mol)	Ki (µM)
Ref01	c1cc(ccc10C2CCN(CC2)c3nc(=0)c4cc(cc(c4s3)N(=0)=0)C(F)(F)F)F	-9,7	0,076
Ref02	c1cc(ccc1C(=0)0C2CCN(CC2)c3nc(=0)c4cc(cc(c4s3)N(=0)=0)C(F)(F)F)F	-10,7	0,014
Ref03	c1c(cc(c2c1c(=0)nc(s2)N3CCN(CC3)NC4CCCCC4)N(=0)=0)C(F)(F)F	-10,9	0,010
Ref04	c1c(cc(c2c1c(=0)nc(s2)N3CCN(CC3)NCC4CCCC4)N(=0)=0)C(F)(F)F	-10,4	0,023
Ref05	c1ccc[cc1]c2nnc[n2C3CCCCC3]SCc4cc[cc[c4]N[=0]=0]N[=0]=0	-9,9	0,054
Ref06	CCCCCCn1c(nnc1SCc2cc(cc(c2)N(=0)=0)N(=0)=0)c3ccccc3	-9	0,249
Ref07	CCCCCCn1c(nnc1SCc2ccccc2)c3cc(cc(c3)N(=0)=0)N(=0)=0	-8,3	0,812
Ref08	c1c(cc(c2c1c(=0)nc(s2)N3CCC4(CC3)SCCS4)N(=0)=0)C(F)(F)F	-8	1,347
Ref09	C0c1cc2c(cc10C)CN(CC2)c3nc(=0)c4cc(cc(c4s3)N(=0)=0)C(F)(F)F	-9,5	0,107
Ref10	COc1ccc(cc1)Cn2c(nnc2SCc3cc(cc(c3)N(=0)=0)N(=0)=0)c4ccccc4	-9,7	0,076
Ref11	FC1=CC=C(0C2CCN(CC2)C(=0)C2CCN(CC2)C2=CC(=NC=N2)N2CC0CC2)C(F)=C1	-9,3	0,150
Ref12	c1ccc(cc1)c2nnc(n2c3ccc(c(c3)Cl)Cl)SCc4cc(cc(c4)N(=0)=0)N(=0)=0	-10,6	0,017
Ref13	c1ccc[cc1]Cn2c[nnc2SCc3ccc[cc3]Br]c4cc[cc[c4]N[=0]=0]C[F][F]F	-9,9	0,054
Ref14	c1c(cc(c2c1c(=0)nc(s2)N3CCOCC3)N(=0)=0)C(F)(F)F	-9,2	0,177
Ref15	0=C(N1CC(C2=C(F)C=C(F)C=N2)=0)C(C3=CC=C(C#N)C=C3)(C)NC1=0	-9	0,249
Ref16	0=C1N(C(C(N1)(C2=CC=C(C#N)C=C2)CC)=0)CC(C3=CC=C(C=C3F)F)=0	-9,4	0,127
Ref17	0=C(N1CC(C2=CC=CC(C)=C2)=0)NC(C3=CC=C(S(=0)(N)=0)C=C3)(C)C1=0	-9,7	0,076
Ref18	0=C(N1CC(C2=CC=CC(F)=C2)=0)NC(C3=CC=C(S(=0)(N)=0)C=C3)(C)C1=0	-8,6	0,489
Ref19	0=C1C2=CC(C(F)(F)F)=CC(N3C(C)=CC=C3C)=C2SC(N4CCN(CC5CCCCC5)CC4)=N1	-8,7	0,413
Ref20	0=C(NC1=C(C(NC(0CC)=0)=0)C=CS1)C2=CC=C(C(N3CCCCC3)=0)C=C2	-10,2	0,033
Ref21	c1c(cc(c2c1c(=S)nc(s2)N3CCN(CC3)CC4CCCCC4)N(=0)=0)C(F)(F)F	-8,8	0,349
ZINC000009429240	Cn1c(=0)c2c(-c3ccccc3)n3c(c2n(C)c1=0)[C@H](c1coc2cccc2c1=0)0CC3	-11,9	0,002
ZINC000021787978	Cc1cccc(-c2c3c(=0)n(C)c(=0)n(C)c3c3n2CC0[C@H]3c2coc3ccccc3c2=0)c1	-11,8	0,002
ZINC000021787983	Cc1cccc(-c2c3c(=0)n(C)c(=0)n(C)c3c3n2CC0[C@@H]3c2coc3ccccc3c2=0)c1	-11,7	0,003
ZINC000252672778	CCCCN1C(=0)C(=c2sc3n(c2=0)[C@@H](c2ccccc2)C(C(=0)0C)=C(C)N=3)c2ccccc21	-11,6	0,003
ZINC00000632944	0=C1/C(=c2\sc3nc4ccccc4n3c2=0)c2ccccc2N1Cc1ccccc1	-11,5	0,004
ZINC000013775581	0=C1/C[=c2/sc3nc4ccccc4n3c2=0]c2ccccc2N1Cc1ccccc1	-11,5	0,004
ZINC000101343925	O=C(Nc1ccccc1)[C@@H]1[C@@H]2C(=O)N(c3ccc4c(c3)OCO4)C(=O)[C@@H]2[C@H]2c3ccccc3C=NN21	-11,5	0,004
	O=C(Nc1ccccc1)[C@@H]1[C@@H]2C(=O)N(c3ccc4c(c3)OCO4)C(=O)[C@H]2[C@@H]2c3ccccc3C=NN12	-11,5	0,004
	0=C1C(=c2sc3nc4ccccc4n3c2=0)c2ccccc2N1Cc1ccccc1	-11,5	0,004
ZINC000002788016	Cc1nn(C)cc1/C=c1\sc2n(c1=0)[C@H]1c3ccccc30[C@@](C)(N=2)[C@@H]1C(=0)Nc1ccccc1	-11,2	0,006
ZINC000008455064	Cc1ccccc1NC(=0)[C@@H]1[C@H]2c3ccccc30[C@]1(C)N=c1s/c(=C/c3cnn(C)c3C)c(=0)n12	-11,2	0,006
ZINC000101455637	CC(=0)N1N=C(c2c(0)[nH]c(=0)n(-c3cccc(Cl)c3)c2=0)C[C@@H]1c1c[nH]c2ccccc12	-11,2	0,006
ZINC000101765650	CCC(=0)N1N=C(c2c(0)[nH]c(=0)n(-c3cccc(Cl)c3)c2=0)C[C@@H]1c1c[nH]c2ccccc12	-11,2	0,006
ZINC000016033791	Cc1cc(C)cc(N2C(=0)[C@@H]3[C@@H](Cc4ccc(0)cc4)N[C@]4(C(=0)Nc5ccc(F)cc54)[C@@H]3C2=0)c1	-11,1	0,007
ZINC000019960761	C0c1ccc2[nH]c3c(c2c1)CCN1C(=0)c2cnc(N4CCCCCC4)nc2C[C@H]31	-11,1	0,007
ZINC000020760244	CC(C)[C@H]1N[C@@]2(c3ccccc3-n3c2nc2cccc2c3=0)[C@H]2C(=0)N(c3ccccc3)C(=0)[C@H]21	-11,1	0,007
ZINC000101765646	CCC(=0)N1N=C(c2c(0)[nH]c(=0)n(-c3cccc(Cl)c3)c2=0)C(C@H]1c1c[nH]c2ccccc12	-11,1	0,007
ZINC000000988062	Cn1c(=0)c2c(nc3n(-c4ccccc4)nc(C(=0)c4ccc5ccccc5c4)n23)n(C)c1=0	-11	0,008
ZINC000013575113	Cn1c(=0)c2c(-c3ccccc3)n3c(c2n(C)c1=0)[C@@H](c1coc2cccc2c1=0)0CC3		
		-11	0,008
ZINC000035538889	CN1C(=0)[C@@H](c2c(-c3ccc4ccccc4c3)[nH]c3[nH]c(=0)[nH]c(=0)c23)c2ccccc21	-11	0,008
ZINC000252517669	0=C(Nc1ccccc1)[C@@H]1[C@@H]2C(=0)N(c3ccc4c(c3)0C04)C(=0)[C@H]2[C@H]2c3ccccc3C=NN12	-	0,008

The compounds with lowest ΔG from reference and ZINC libraries were indicated as bold.

The amino acid library containing 100 sequences of DprE1 mostly from diverse strains did not reveal any mutation profiles in amino acids interacting with compounds ZINC000009429240 and Ref3.

The prepared mutation library of DprE1 is included in the Supplementary Figure 1.



DISCUSSION

In the current study, virtual screening was performed using molecular docking with the ZINC20 database¹¹ to search for potent inhibitors against the DprE1 enzyme of *M.tuberculosis* and compared with DprE1 inhibitors reported in the literature.¹² The analysis identified 21 compounds with a binding energy range of -11 to -11.9 as the top-ranked molecules. Both ZINC000009429240 and Ref3 demonstrated a strong interaction with the enzyme cavity, exhibiting a ΔG of -11.9 and -10.9, respectively. These interactions involved H-bonding with amino acid positions of 228S and 418K versus 132H, 228S and 60Y, and hydrophobic interactions with 116P, 131I, 316P, 365V and 415Y versus 116P, 316P and 365V for ZINC000009429240 and Ref3, respectively. Additionally, it was observed that the amino acids at positions of 228S, 116P, 316P and 365V played an important role as they interacted with both ZINC000009429240 and Ref3. When compared with the prepared mutation library of DprE1, it turned out that these interacting amino acids were not affected by mutations in the enzyme.

In recent years, various proteins of *M.tuberculosis* have been targeted for screening of novel and potent inhibitors through various compound databases. The target proteins involved in various studies were DprE1,¹⁹ adenylating enzymes of AspS and KatG,²⁰ protein kinase B (PknB),²¹ glutamine synthetase (GS) in the nitrogen metabolism and cell wall synthesis,²² β-ketoacyl-acyl carrier protein KasA,²³ malonyl Co-A acyl carrier protein transacylase (FabD),²⁴ 7,8-diaminopelargonic acid synthase (BioA),²⁵ and many others. Among these target proteins, DprE1 is particularly important due to its essential role in the synthesis of arabinogalactan and lipoarabinomannan, which are crucial components in mycobacterial cell wall biogenesis.²⁶

Zgang et al.,²⁶ identified potential inhibitors from a virtual screening of 135,755 selected molecules in the ChemDiv dataset, which is also linked to the ZINC database. ZINC09833455 and ZINC32996629 were determined as hit compounds to inhibit DprE1. Due to their availability, certain compounds labeled as "for sale", but not "in stock", and the compounds outside the specified range of physicochemical descriptors such as TPSA and/or logP were excluded from this study. Kumar et al.,¹⁹ conducted a virtual screening of bioactive molecules from the ChEMBL database against DprE1. They identified 4 compounds (ChEMBL2441313, ChEMBL2338605, ChEMBL441373, ChEMBL1607606) as potential inhibitors. However, these were excluded in this study because their molecular weights fell outside the specified range. Anand et al.,²⁷ once again utilized the ZINC database for virtual screening against a modeled DprE1 enzyme, screening a total of 19,365 molecules and identifying the top 10 hit molecules (ZINC06142089, ZINC18116975, ZINC00856140, ZINC01800489, ZINC06142069, ZINC06142038, ZINC03953443, ZINC01886310, ZINC01750499, ZINC11582332) with docking scores ranging from -5.8 to -8 kcal/ mol. These compounds were not included in our library, possibly due to their mutagenicity characteristics. However, the docking scores for these compounds are lower than those of our hit molecules (-11 and -11.9) in the ZINC20 database. According to ZINC20, PubChem (https://pubchem.ncbi.nlm.nih.gov) and Pubmed (https://pubmed.ncbi.nlm.nih.gov) databases (accessed on March 30, 2024), none of the top-ranked compounds of ZINC20 have been reported as potential inhibitors of DprE1.

It's important to note that there is no consensus approach for

virtual screening and thus docking scores can vary for the same compounds and targets. Additionally, although the DprE1 enzyme has been an important target in virtual screening studies, none of them contain a selective library based on physicochemical properties of DprE1 inhibitors known from *in-vitro* data in the literature. Despite high binding affinity data obtained from various virtual screening studies, enabling these hit molecules to penetrate the highly complex cell wall of *M. tuberculosis* may require more stringent physicochemical features which could enhance their efficiency when tested in-vitro. Virtual screening is becoming increasingly important to discover new compounds that will inhibit essential molecules of *M. tuberculosis*. Data obtained from virtual screening has the potential to develope drug-like compounds into potent drug molecules.

CONCLUSION

Overall, we suggested a mostly diverse group of compounds as potent inhibitors of the DprE1 enzyme of *M. tuberculosis.* It would be highly interesting to evaluate the effectiveness of these hit compounds *in-vitro* to validate our approach further. The data gathered in this study may have potential to be developed into effective drug molecules.

Ethics Committee Approval: Ethical approval was not necessary due to the totally in-silico design of the study.

Informed Consent: Informed consent was not necessary due to the totally in-silico design of the study.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept – N.Y., S.A., G.D.; Design – N.Y., S.A., G.D.; Data Collection and/or Processing – N.Y., S.A., G.D.; Analysis and/or Interpretation – N.Y., S.A., G.D.; Writing – N.Y., S.A., G.D.

Declaration of Interests: The authors have no conflict of interest to declare.

Funding: The authors declared that this study has received no financial support.

References

- Salina EG. Mycobacterium tuberculosis infection: Control and treatment. *Microorganisms*. 2023 Apr 18;11(4):1057. [Crossref]
- Chakaya J, Khan M, Ntoumi F, et al. Global Tuberculosis Report 2020 Reflections on the Global tuberculosis report 2020 Reflections on the global TB burden, treatment and prevention efforts. *Int J Infect Dis.* 2021;113 Suppl 1(Suppl 1):7-12. [Crossref]
- Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens *Nat Rev Drug Discov.* 2013 May;12(5):388-404. [Crossref]
- Singh V, Chibale K. Strategies to combat multi-drug resistance in tuberculosis. *Acc Chem Res.* 2021 May 18;54(10):2361-2376. [Crossref]
- Oh S, Trifonov L, Yadav VD, et al. Tuberculosis drug discovery: a decade of hit assessment for defined targets. *Front Cell Infect Microbiol.* 2021;11:611304. [Crossref]
- Abrahams KA, Batt SM, Gurcha SS, et al. Dpre2 is a molecular target of the anti-tubercular nitroimidazole compounds pretomanid and delamanid. *Nat Commun.* 2023;14(1):3828.

[Crossref]

- MakarovV, NeresJ, Hartkoorn RC, et al. The 8-pyrrole-benzothiazinones are noncovalent inhibitors of Dpre1 from mycobacterium tuberculosis. *Antimicrob Agents Chemother*. 2015;59(8):4446-52. [Crossref]
- Tiwari R, Miller PA, Chiarelli LR, et al. Design, syntheses, and anti-TB activity of 1,3-benzothiazinone azide and click chemistry products inspired. by BTZ043. ACS Med Chem Lett. 2016;7(3):266-270. [Crossref]
- 9. Chikhale R, Menghani S, Babu R, et al. Development of selective Dpre1 inhibitors: Design, synthesis, crystal structure and antitubercular activity of benzothiazolylpyrimidine-5-carboxamides. *Eur J Med Chem.* 2015;96:30-46. [Crossref]
- 10. Naidu A, Nayak SS, Lulu S S, et al. Advances in computational frameworks in the fight against TB: The way forward. *Front Pharmacol.* 2023;14:1152915. [Crossref]
- Irwin JJ, Tang KG, Young J, et al. ZINC20-A free ultralarge-scale chemical database for ligand discovery. *J Chem Inf Model.* 2020;60(12):6065-6073. [Crossref]
- Amado PSM, Woodley C, Cristiano MLS, et al. Recent advances of Dpre1 inhibitors against mycobacterium tuberculosis: Computational analysis of physicochemical and ADMET properties. ACS Omega. 2022;7(45):40659-40681. [Crossref]
- Sander T, Freyss J, von Korff M, Rufener C. Datawarrior: An open-source program for chemistry aware data visualization and analysis *J Chem Inf Model*. 2015;55(2):460-473. [Crossref]
- Benet LZ, Hosey CM, Ursu O, et al. BDDCS, The rule of 5 and drugability. *Adv Drug Deliv Rev.* 2016 Jun 1;101:89-98. [Crossref]
- Trott O, Olson AJ. Autodock vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J Comput Chem.* 2010;31(2):455-461. [Crossref]
- Dallakyan S, Olson AJ. Small-molecule library screeningby docking with pyrx. *Methods Mol Biol.* 2015;1263:243-50. [Crossref]
- Neres J, Hartkoorn RC, Chiarelli LR, et al. 2-carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of Dpre1. ACS Chem Biol. 2015;10(3):705-14. [Crossref]
- Schrödinger L, DeLano W. PyMOL. 2020. Retrieved from http://www.pymol.org/pymol
- Niranjan K, Srivastava R, Prakash A, et al. Virtual screening and free energy estimation for identifying mycobacterium tuberculosis flavoenzyme Dpre1 inhibitors. *J Mol Graph Model*. 2021;102:107770. [Crossref]
- Collins AP, Abdelfattah W. Structure-based virtual screening of essential mycobacterium tuberculosis enzymes AspS and KatG for potential inhibitors. *Bioinformation*. 2021;17(1):101-108. [Crossref]
- Thongdee P, Hanwarinroj C, Pakamwong B, et al. Virtual screening to identify novel potential inhibitors for glutamine synthetase of mycobacterium tuberculosis. PknB with Antibacterial Activity. *J Chem Inf Model*. 2022;62(24):6508-6518. [Crossref]
- Kumari M, Subbarao N. Virtual screening to identify novel potential inhibitors for glutamine synthetase of mycobacterium tuberculosis. *J Biomol Struct Dyn.* 2020;38(17):5062-5080.
 [Crossref]
- 23. Andrianov AM, Furs KV, Gonchar AV, et al. Virtual screening and identification of promising therapeutic compounds against drug-eesistant mycobacterium tuberculosis B-ketoacylacyl carrier protein synthase I (KasA). *J Biomol Struct Dyn.* 2023:1-13. [Crossref]

- 24. Sundararajan S, Karunakaran K, Muniyan R. Structure based virtual screening and discovery of novel inhibitors against FabD protein of mycobacterium tuberculosis. *J Biomol Struct Dyn.* 2023:1-12. **[Crossref]**
- 25. Singh S, Khare G, Bahal RK, et al. Identification of mycobacterium tuberculosis BioA inhibitors by using structure-based virtual screening. *Drug Des Devel Ther.* 2018;12:1065-1079.

[Crossref]

- Zhang G, Guo S, Cui H, et al. Virtual screening of small molecular inhibitors against DprE1. *Molecules*. 2018;23(3):524.
 [Crossref]
- 27. Anand R. Identification of potential antituberculosis drugs through docking and virtual screening. *Interdiscip Sci.* 2018;10(2):419-429. [Crossref]

Stratument Stratu	ода жарыа жарындан алааны такалатта жарылар жаралар жаралар жарар жаралар жаралар жаралар жаралар жаралар жара 1996 д. Ортан Арадонија				化化学 化化合金 化化合金 化合金 化合金 化合金 化合金 化合金 化合金 化合金 化
In triant of DprtI Gene (Covering Positions 1 to 430) Obtained from Genbank Using Bickdit v.725	TV A CERIX A DESIGN				
It Floure 1. Mutation Library of DrEI Gene (Covering Positions 1 to 430) Obtained from Genbark Using BioEdit v.725	2021217001 dectament		A		
Interference Interference	22 LANUTALL ONLINE 201. A Chale A Protecher				
Image: Sector Sector Positions 1 to 430 Obtained from Constrained from Constr	LAEATAN I contractor				A
Image: Sector	VP DICERT ANDRE				
Image: Sector	VERDAR MAD 1 Accessor				
Image: Sector					
Image: Sector	NP DITATIAL desper				
Image: Sector	102 002 002 001 1 0 000 000				
<pre>A Figure 1. Mutation Library of DprEl Gene (Covering Positions 1 to 430) Obtained from Genbark Using BioEdit v.7.25</pre>	WD BESELSE MUCHE				
Image: Sector	100 05 114 118 1 destroat				
Image: Sector	another State and Annual State and Annua				
<pre>in Figure 1. Mutation Library of DprEI Gene (Covering Positions 1 to 430) Obtained from Genbank Using BioEddit v.7.25</pre>	W2 10 13-50 determined				
<pre>in Figure 1. Mutation Library of DprE1 Gene (Covering Positions 1 to 430) Obtained from Genbank Using BioEdit v.2.5</pre>	707 0512 (2114) decipert				
Image: Sector	Transferration Control of Control	4			
<pre>in Figure 1. Mutation Library of DrEI Gene (Covering Positions 1 to 430) Obtained from Genbank Using BioEdit v.7.25</pre>	311-176 1.030000- CM				A second s
Image: Sector	705 1011011 decrement				and the second s
<pre>i f f f f f f f f f f f f f f f f f f f</pre>					
<pre>in Figure 1. Mutation Library of DprEl Gene (Covering Positions 1 to 430) Obtained from Genbank Using BioEdit v.7.25</pre>					
<pre>in Figure 1. Mutation Library of DprEI Gene (Covering Positions 1 to 430) Obtained from Genbank Using BioEdit v.7.25</pre>				×	
L Figure 1. Mutation Library of DprEl Gene (Covering Positions 1 to 430) Obtained from Genbank Using BioEdit v.2.5					
<pre></pre>					
<pre>int Figure 1. Mutation Library of DprEl Gene (Covering Positions 1 to 430) Obtained from Genbank Using BioEdit v.7.25</pre>			0		
<pre>http://withintia.com/initialized initialized init</pre>	COLDERON: enforcements			3	
Ligure 1. Mutation Library of DprE1 Gene (Covering Positions 1to 430) Obtained from Genbark Using BioEdit V.7.25	N/2 121 13224 Jacquest				
Image: Sector	W2 05/152-06.1 decimate 0				
Image: Sector	Synamics I at the Market of th				
Image: Sector					
Image: Sector	W20205070M1 deapert				
Image: Sector	Terra Entra 1911 A decimant				
Line 1. Mutation Library of DprEI Gene (Covering Positions 1 to 430) Obtained from Genbank Using BioEdit v.7.25	ST NOT 21 on American		PL I		
Let Library of DprEl Gene (Covering Positions 1to 430) Obtained from Genbank Using BioEdit v.7.25	COCORTER 1 and onderer		And the second sec		A CONTRACTOR OF A CONTRACT
Let Library of DprEl Gene (Covering Positions 1 to 430) Obtained from Genbank Using BioEdit v.7.2.5	The second se		DA		
Let Figure 1. Mutation Library of DprEI Gene (Covering Positions 1 to 430) Obtained from Genbank Using BioEdit v.7.25	W2 #22 #22 #22 #12 #12 #12 #12 #12 #12 #1				
د * * * * * * * * * * * * * * * * * * *	THE LEASE STATE AND A PARTICULAR AND A P				
د المعادمة المحالية المحال المحالية المحالية المحالي محالية المحالية المح محالية المحالية اح	The colored and and a second a				
د المعادمة المحالية المحال المحالية المحالية المحالي المحالية المحالية ال محالية المحالية اح	V/2 15164 3091.1 decement				
ent Figure 1. Mutation Library of DprEl Gene (Covering Positions 1 to 430) Obtained from Genbank Using BioEdit v.7.25	1001 00 00 00 00 00 00 00 00 00 00 00 00				
المعادمة المعادمة المحالية ا محالية المحالية المحالي محالية المحالية المح المحالية المحالية	THORE AND A DESCRIPTION OF A DESCRIPTION				
المعادمة الم	W3100115411 deapert				
ی از مراجع ا A a a a a b and Using BioEdit v.7.2.5 and Figure 1. Mutation Library of DprEl Gene (Covering Positions 1 to 430) Obtained from Genbank Using BioEdit v.7.2.5	Average of a second sec				
المعادمة المعادمة المحادثة المحادث محددث المحادث المحادث المحادثة المحادث محددث المحادث المحادث المحادثة محادثة المحادثة المحادثة المحادث المحادث المحادث المحادث المحادث المحادث المحادث المحادث محادث محادث محادث محادث محادث محادث محادثة محادثة محادث محادثة محادثة محادثة محادثة محادثة محادثة محادثة محادثة مح	10E. A Divise A Divises			_	
المعادمة الم معادمة المعادمة المعاد A Figure 1. Mutation Library of DprEl Gene (Covering Positions 1 to 430) Obtained from Genbank Using BioEdit v.7.2.5	CUNDERD 2 stateowdstan			9	
المعادمة الم معادمة المعادمة المعاد A Figure 1. Mutation Library of DprE1 Gene (Covering Positions 1 to 430) Obtained from Genbank Using BioEdit v.7.2.5	CEORDS and All				
Supplement Figure 1. Mutation Library of DprEl Gene (Covering Positions 1 to 430) Obtained from Genbank Using BioEdit v.7.2.5	VO 231 N1 (024 - dec. press	L.			
Supplement Figure 1. Mutation Library of DprE1 Gene (Covering Positions 1 to 430) Obtained from Genbank Using BioEdit v.7.2.5	DQ.54501. coloredorus	······································			······································
Supplement Figure 1. Mutation Library of DprEl Gene (Covering Positions 1 to 430) Obtained from Genbank Using BioEdit v.7.2.5	Tangan 1991 1991 1991 1991 1991 1991 1991 19		DA DA		
Supplement Figure 1. Mutation Library of DprEl Gene (Covering Positions 1 to 430) Obtained from Genbank Using BioEdit v.7.2.5	1				and the second
Supplement Figure 1. Mutation Library of DprEI Gene (Covering Positions 1 to 430) Obtained from Genbank Using BioEdit v.7.2.5					
Supplement Figure 1. Mutation Library of DprEI Gene (Covering Positions 1 to 430) Obtained from Genbank Using BioEdit v.7.2.5	1.1				
Supplement Figure 1. Mutation Library of DprEl Gene (Covering Positions 1 to 430) Obtained from Genbank Using BioEdit v.7.2.5	N.9 101111101 despect				
Supplement Figure 1. Mutation Library of DprEI Gene (Covering Positions 1 to 430) Obtained from Genbank Using BioEdit v.7.2.5	2012 3 201 58 208 0 december 1				
Supplement Figure 1. Mutation Library of DprE1 Gene (Covering Positions 1 to 430) Obtained from Genbank Using BioEdit v.7.2.5					
JUDDICINENT 1901 TITURATION FINAL OF TO CONCINUE TO	Supplement Figure 1 Mutation Library of D	ייירדו הפהם לת	Overing Docitions 14	to 430) Obtained from Genhank I Ising BioEdit v 70 5	
	Jappielle I 19 ale 1. Hatation Fiblian y of D				

T		210	200	300	310 320	330	940	350 360	94E	330	390	017 001	420	430
SUILP A Chain A Decemen B 47DN A Chain A middendu	LORANSSORLATVECUPAKLESSEPLK	DAPQLETEPEVEPN	OLANKYTEOPIOE	LWYRX SOLYRORY	CNL TQPYHPLEME	GEWNRAYODAGYLC	TOPVIDIEAVE	PKKITOVICASOHY	S PL DV PKL P OP B N	CAPL SEP (PC0N	ICVDFP IXDeC 0	CFV38LDRRVLEPOOR	VTAKDSRTTAE	BURNERS.
SHIV A Chain A Deciprent.														
WP 168728760.1 decement														(*)* (*)* (*)
WP 220019913.1 decrement														-
AAKARISE I on forestructure														
CICM17602.1 outdoeducta														
WP 001669105.1 deceptern -			「「「「」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」	*************					Carl and a second second					ちゃ たまま あま
ULB 15 3485 482 1 Aprendit														4
WP 1144614041 FAC-bit														
WD 081747314.1 decement -	Q													*******
WP 059436017.1 decement				「「「「「」」」」」」」」」」」」」										434 × 14 × 14 4
Transform Transformer and														
The second is a second with														
The state of the state of the							×							
Landston the test of the Aut														
The state of the second state of the														
- Landrag French John AM														
- Lessen to the state of the														
Landren Trootforent AM														
Wednesd Transformer AM														
WP 140255577 MULTISC														
WP 10333 1301.1 decement			「「「「「」」」」」」」」」」」」」		二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十	「「「「」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」		人 ちちちちちちちちちちちちちちちちちちちちちちちちちちちちちちちちちち ちちちち			and a state of the			
WP 1423027061 decigeent														Contraction of the local division of the loc
CNUG (304.1 excloreducts -														
We 10282001180011900														
CMURDOLOGI LADORDICAL														
Who could be a state of the second who														
WIND DIGSTOCKET CONCERNING														Constant and
WP 001/140851 decement -		a state of the sta												
Chronestan endenstante														
CKL89106.1 condereductan -			「日本のとうち」をあるとうという		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~				二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十		Contraction of the local division of the loc	「キャートー」というないというという	Conceptual and the second	
WP 0512495341 decigent												the second second second		
CKO54345.1 exidered actail -														· · · · · · · · · · · ·
WP 057131456.1 decepter: -			A NUMBER OF STREET, ST						And a state of the		Annual Contraction of the other of the other oth	and the second s	and a second sec	· · · · · · · · · · · · · · · · · · ·
Strategy LOTENEASEN														(H)
- meaning [#:915(150 d/m	- and the second s		Contraction of the			Carrier and a second and a second sec	I		Contraction and Auto		the second secon	Contraction of the second seco	and a second second	A Street and
WID TONS AS NOT THE MAN														
0.0 641 60 T041 de martin														
WE ON 731 6074 1 ANTWO														
WTD 051705203 1 decrement													0.	
and an and a second sec														
CTCMM0428 1 and Annual and														
WD 68140401 1 Aprenda		and the second s					and a second sec							
and a second sec														
0.0 0.1400051 1 Acres														
THE PACESCONE MANAGEMENT														
The second secon														
Compared 1 12 1 12 1 10 100														
TUT AT AT AN TANK TANK											2			
Contraction of the second second second														
AND														-
Database Foresaute JAM														
Churchens / all endersoners														
WP UDICE LIVES LIVES TO DESTIN														
- Transferrary in a second point of the														
Contraction of the second seco														
Contraction of the second seco														
PTD 66070 1 and 4 and 4 and 4 and 4								0						
UD 102056258 1 deserves														
THE OTHER PARTY IN THE PARTY OF														
TRAFFIC TOTAL TOTAL														
THE PARTY AND TH														
The second is the second first														
- Tanganan Later C. C. M. C.						States - States								
Tanganan tangang ang ang													0 0	
- Landacen Frechologica AM													the state of the s	
ATT ACTOR TO ATT ATT ATT ATT ATT ATT ATT ATT ATT														
WP 0013112361 decempt				***********					こうてんし うちち やちちんち		and the second		二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十	
WP 252155-981 06000														
ALINS 700.1 OURDONDOCIAN					and the second se		A CONTRACTOR OF A CONTRACTOR O		the second second second			the second s		
		() () () () () () () () () () () () () () ()			-	1 	· · ·			
Supplement	Supplement Figure 1. Multation Library of DorFT Gene (covering positions 1 to 4 30) Obtained from Genhank Using BioEdit v 771 (cont.)	stary of Do	י שטשיט (<u>א</u> ר	novering r	ositions]	to 430) Or	otained tro	am Genhar	R L Ising B	DFOIT V 7	71 (cont)			
		קטוטעוטי	シットシントコー								\ \ \ \ \ \			